These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
328 related items for PubMed ID: 21412911
21. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Hornberger J, Robertus K. Ann Intern Med; 2006 Sep 05; 145(5):317-25. PubMed ID: 16954357 [Abstract] [Full Text] [Related]
22. Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial. Simberkoff MS, Arbeit RD, Johnson GR, Oxman MN, Boardman KD, Williams HM, Levin MJ, Schmader KE, Gelb LD, Keay S, Neuzil K, Greenberg RN, Griffin MR, Davis LE, Morrison VA, Annunziato PW, Shingles Prevention Study Group. Ann Intern Med; 2010 May 04; 152(9):545-54. PubMed ID: 20439572 [Abstract] [Full Text] [Related]
23. Review of the Persistence of Herpes Zoster Vaccine Efficacy in Clinical Trials. Cook SJ, Flaherty DK. Clin Ther; 2015 Nov 01; 37(11):2388-97. PubMed ID: 26602282 [Abstract] [Full Text] [Related]
24. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Rothberg MB, Virapongse A, Smith KJ. Clin Infect Dis; 2007 May 15; 44(10):1280-8. PubMed ID: 17443464 [Abstract] [Full Text] [Related]
25. Cost-effectiveness of vaccination against herpes zoster and postherpetic neuralgia: a critical review. Kawai K, Preaud E, Baron-Papillon F, Largeron N, Acosta CJ. Vaccine; 2014 Mar 26; 32(15):1645-53. PubMed ID: 24534737 [Abstract] [Full Text] [Related]
26. Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. Keating GM. Drugs; 2013 Jul 26; 73(11):1227-44. PubMed ID: 23839657 [Abstract] [Full Text] [Related]
27. Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records. Klein NP, Bartlett J, Fireman B, Marks MA, Hansen J, Lewis E, Aukes L, Saddier P. BMJ; 2023 Nov 08; 383():e076321. PubMed ID: 37940142 [Abstract] [Full Text] [Related]
28. Topical lidocaine for the treatment of postherpetic neuralgia. Khaliq W, Alam S, Puri N. Cochrane Database Syst Rev; 2007 Apr 18; (2):CD004846. PubMed ID: 17443559 [Abstract] [Full Text] [Related]
29. [Herpes zoster and postherpetic neuralgia: advantages of the vaccination]. Cañada JL. Rev Esp Quimioter; 2009 Nov 18; 22 Suppl 1():19-21. PubMed ID: 20084344 [No Abstract] [Full Text] [Related]
30. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh SS, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan IS, Wang WW, Annunziato PW, Silber JL, Shingles Prevention Study Group. N Engl J Med; 2005 Jun 02; 352(22):2271-84. PubMed ID: 15930418 [Abstract] [Full Text] [Related]
31. Effectiveness and safety of the recombinant herpes zoster vaccine in different population groups: a systematic review and meta-analysis. Bengolea A, Chamorro F, Ramos JT, Rada G, Catalano HN, Izcovich A. Medicina (B Aires); 2024 Jun 02; 84(5):959-970. PubMed ID: 39399936 [Abstract] [Full Text] [Related]
33. Budget-Impact Analysis of Alternative Herpes Zoster Vaccine Strategies: A U.S. HMO Perspective. Graham J, Mauskopf J, Kawai K, Johnson KD, Xu R, Acosta CJ. J Manag Care Spec Pharm; 2016 Jul 02; 22(7):872-88. PubMed ID: 27348287 [Abstract] [Full Text] [Related]
34. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis. McGirr A, Widenmaier R, Curran D, Espié E, Mrkvan T, Oostvogels L, Simone B, McElhaney JE, Burnett H, Haeussler K, Thano A, Wang X, Newson RS. Vaccine; 2019 May 16; 37(22):2896-2909. PubMed ID: 30982636 [Abstract] [Full Text] [Related]
35. Shingles (Herpes Zoster) Vaccine (Zostavax(®)): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia. Keating GM. BioDrugs; 2016 Jun 16; 30(3):243-54. PubMed ID: 27189459 [Abstract] [Full Text] [Related]
36. Zostavax : a subcutaneous vaccine for the prevention of herpes zoster. Doan HQ, Ung B, Ramirez-Fort MK, Khan F, Tyring SK. Expert Opin Biol Ther; 2013 Oct 16; 13(10):1467-77. PubMed ID: 23984934 [Abstract] [Full Text] [Related]
37. Herpes zoster vaccine: clinical trial evidence and implications for medical practice. Burke MS. J Am Osteopath Assoc; 2007 Mar 16; 107(3 Suppl 1):S14-8. PubMed ID: 17488883 [Abstract] [Full Text] [Related]
38. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations. Prosser LA, Harpaz R, Rose AM, Gebremariam A, Guo A, Ortega-Sanchez IR, Zhou F, Dooling K. Ann Intern Med; 2019 Mar 19; 170(6):380-388. PubMed ID: 30776797 [Abstract] [Full Text] [Related]
39. Vaccination against herpes zoster in developed countries: state of the evidence. Drolet M, Oxman MN, Levin MJ, Schmader KE, Johnson RW, Patrick D, Mansi JA, Brisson M. Hum Vaccin Immunother; 2013 May 19; 9(5):1177-84. PubMed ID: 23324598 [Abstract] [Full Text] [Related]
40. [Herpes zoster and postherpetic neuralgia - prevention by vaccination?]. Wutzler P. Dtsch Med Wochenschr; 2009 Apr 19; 134 Suppl 2():S90-4. PubMed ID: 19353479 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]